10 Vertex Pharmaceuticals business development leaders
These Vertex Pharmaceuticals business development leaders hold senior vice president, executive director, senior director and director titles in business development, external innovation, BD finance and alliance management. A reader can learn how business development leaders work at Vertex Pharmaceuticals from people who have held the role.
Professionals to explore
Aaron Reames
LinkedInExperience: Senior Vice President, Business Development and External Innovation · Vertex Pharmaceuticals
Aaron Reames has been Senior Vice President, Business Development and External Innovation at Vertex Pharmaceuticals since June 2018. Aaron Reames was Senior Equity Analyst, Biotechnology and Healthcare Team Lead at Columbia Threadneedle Investments, US (2010–2018) and Director, Equity Research at Wells Fargo Securities (2007–2010).
Christopher Folts
LinkedInExperience: Director - BD/Transactions & Alliance Management · Vertex Pharmaceuticals
Christopher Folts has been Director - BD/Transactions & Alliance Management at Vertex Pharmaceuticals since March 2024. At Vertex Pharmaceuticals, Christopher Folts also held Associate Director (2023–2024) and Senior Manager (2021–2023) titles in BD/Transactions & Alliance Management, and was Research Scientist II (2019–2021) and Research Scientist I (2018–2019).
Dhru Patel
LinkedInExperience: Executive Director, Head of Early Pipeline BD - Global Commercial Strategy · Vertex Pharmaceuticals
Dhru Patel has been Executive Director, Head of Early Pipeline BD - Global Commercial Strategy at Vertex Pharmaceuticals since May 2026. At Vertex Pharmaceuticals, Dhru Patel was also Team Lead (Senior Director), External Innovation - Business Development (2023–2026), Sr. Director, Portfolio Innovation & Operations, Business Development (2021–2023) and Director, Team Lead for Corporate AI Team (2017–2021).
Dugan Reagan
LinkedInExperience: Executive Director- Business Development · Vertex Pharmaceuticals
Dugan Reagan has been Executive Director- Business Development at Vertex Pharmaceuticals since July 2026. At Vertex Pharmaceuticals, Dugan Reagan also held Sr. Director (2022–2026), Director (2019–2022), Sr. Manager (2019) and Manager (2017–2019) titles in Business Development.
Ernesto M Massimo
LinkedInExperience: Executive Director, Strategic and BD Finance · Vertex Pharmaceuticals
Ernesto M Massimo has been Executive Director, Strategic and BD Finance at Vertex Pharmaceuticals since February 2024, and was Head of Business Development Finance there (2021–2024). Ernesto M Massimo was Director - BD&L Finance at Novartis (2017–2021) and Finance Manager - R&D at Insulet Corporation (2016–2017).
Hannah Gardocki
LinkedInExperience: Director, Alliance Management · Vertex Pharmaceuticals
Hannah Gardocki has been Director, Alliance Management at Vertex Pharmaceuticals since February 2026, and was Associate Director, Business Development Transactions & Alliance Management there (2024–2026). Hannah Gardocki also held a launch role at Vertex Pharmaceuticals (2021–2024) and a CAR T marketing role at Bristol Myers Squibb (2020–2021).
Kelsey Tsai, CFA
LinkedInExperience: Director, BD and Strategic Finance · Vertex Pharmaceuticals
Kelsey Tsai has been Director, BD and Strategic Finance at Vertex Pharmaceuticals since June 2025. Kelsey Tsai was Vice President, Sandbox Healthcare (2021–2024) and Associate, Sandbox Healthcare (2020–2021) at Sandbox Industries, and Founder & Consultant at Merino Advisors (2024–2025), according to the profile.
Maggie Lee
LinkedInExperience: Director, Business Development - External Innovation · Vertex Pharmaceuticals
Maggie Lee has been Director, Business Development - External Innovation at Vertex Pharmaceuticals since February 2025, and the profile lists Associate Director, External Innovation and Business Development there from 2022 to 2025. Maggie Lee was Associate Director, Medical Affairs at Apellis Pharmaceuticals (2021–2022) and Senior Manager, Global Medical Communications at Vertex Pharmaceuticals (2017–2021).
Mary Pirone
LinkedInExperience: Vice President, Portfolio & Program Managemeent · Vertex Pharmaceuticals
Former Executive Director, Head of Alliance Management at Vertex Pharmaceuticals (2022–2026). Mary Pirone was also Senior Director, BD - Transactions and Alliance Management at Vertex Pharmaceuticals (2019–2022), has been Vice President, Portfolio & Program Managemeent there since March 2026, and was Senior Director Corporate Planning and Head of Alliance Management at ImmunoGen, Inc. (2016–2019).
Nicola L. Beer
LinkedInExperience: Senior Director - BD - External Innovation & Outreach · Vertex Pharmaceuticals
Nicola L. Beer has been Senior Director - BD - External Innovation & Outreach at Vertex Pharmaceuticals since February 2026, and the profile also lists Senior Director - Integrative Biology at Vertex Pharmaceuticals from 2021. Nicola L. Beer was Director - Digital and Early Target Biology at Vertex Pharmaceuticals (2021) and Senior Head of Department | Discovery Biology and Pharmacology at Novo Nordisk (2018–2019).
Choose the right perspective
Pick someone from external innovation or early pipeline business development for questions about finding outside science, and someone from transactions or alliance management for questions about structuring and running a partnership. Pick someone from BD finance when the question is about how a deal is valued and budgeted.
Questions to take into the conversation
- 01How does a biotech business development group decide which outside science to pursue?
- 02What does alliance management involve after a biotech signs a collaboration?
- 03How do business development and finance teams work together to value a licensing opportunity?
Reaching Vertex Pharmaceuticals business development leaders
How can I contact one of these Vertex Pharmaceuticals business development leaders?
Pick one of the 10 people on this page and choose "Book a paid call", or describe your project to find others. You offer a fee for a 15-minute call or a written answer, Instant Expert finds the person's work email and sends the invitation, and they decide whether to accept. The list covers 1 company: Vertex Pharmaceuticals, based on profile data retrieved on October 26, 2026. Being listed here doesn't mean someone has agreed to take calls.
How much does it cost to reach Vertex Pharmaceuticals business development leaders?
You choose the offer, starting at $5 per person. The offer is what the person receives, and Instant Expert's fee is added on top, so a $100 offer costs you $125. The fee is 20% of what you pay. You're charged only when the person books the call or sends the answer.
What if they don't reply?
You pay nothing. Instant Expert sends follow-up reminders, and if the person hasn't booked or answered within 7 days, the request expires and any hold on your card is released. You can invite several of the 10 people on this list at once and cap your total spend, so you pay only for the ones who accept.
Can an AI agent ask one of these Vertex Pharmaceuticals business development leaders a question?
Yes. An agent with a USDC wallet on Base can ask one question without an Instant Expert account. It names the person, for example by the LinkedIn URL on this page, and pays per ask over x402 (HTTP 402). The person answers in writing or by voice note, and if nobody answers within 7 days, the payment goes back to the wallet automatically. Claude and ChatGPT can do the same through the Instant Expert connector: setup is at /docs/mcp for Claude and /docs/chatgpt for ChatGPT. x402 docs
About this directory
This is a professional research starting point based on business profile data retrieved on . Titles and companies reflect that source snapshot; roles marked former had ended by then. Check the linked profiles for current details. Inclusion does not imply Instant Expert membership or availability.